/Vision and strategy
Vision and strategy 2018-05-03T07:19:37+00:00

About

Vision and strategy

Relaxera is a pharmaceutical company focused on the development of a treatment of the aging heart (Heart Failure with preserved Ejection Fraction – HFpEF) and on protecting pancreatic cells against the glucotoxic effects caused by impaired glucose tolerance.  Our pharmaceutical candidate is relaxin-2, a member of the family of insulin-like hormones, which is released into the blood stream during partition and known for its pleiotropic effects in the human body. Relaxera has developed methods for its synthesis in large quantities and is examining its effects on the heart muscle fibres and on the islet cells of pancreas.

About Relaxera - bringing back vitality

Vision and Strategy

Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with human relaxin-2 for chronic cardiovascular diseases and (pre-)diabetic conditions.

In spite of the manifold beneficial actions of relaxin-2 in cardiovascular (patho)physiology Relaxera will focus its activities on the use of synthetic human relaxin-2 for the treatment of the aging heart, heart failure with preserved ejection fraction, and the delay of the onset of type-2 diabetes in obese and overweight patients suffering from impaired glucose tolerance.

Vision and Strategy

Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (“Relaxera”) is a company dedicated to the development of pharmaceuticals and treatments with human relaxin-2 for chronic cardiovascular diseases and (pre-)diabetic conditions.

In spite of the manifold beneficial actions of relaxin-2 in cardiovascular (patho)physiology Relaxera will focus its activities on the use of synthetic human relaxin-2 for the treatment of the aging heart, heart failure with preserved ejection fraction, and the delay of the onset of type-2 diabetes in obese and overweight patients suffering from impaired glucose tolerance.